EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS
- 1 May 2005
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 33 (5) , 637-643
- https://doi.org/10.1124/dmd.104.003442
Abstract
The function of breast cancer resistance protein (BCRP) and its role in drug absorption, distribution, and elimination has recently been evaluated. The objective of the present study was to examine the expression, localization, and functional characteristics of BCRP in Caco-2 cells, a widely used human intestinal epithelial cell model for investigating intestinal drug absorption. The expression of BCRP in Caco-2 cells was measured by Western blotting using the antibody BXP-21. Localization of BCRP was determined by an immunofluorescence technique using both antibodies BXP-21 and BXP-34. The drug efflux function of BCRP was evaluated via the epithelial transport of methotrexate (MTX) and estrone-3-sulfate (E3S) across Caco-2 cell monolayers in the presence or absence of the BCRP inhibitors Ko143 or GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide). Results from Western blot assay indicated that Caco-2 cells in the late passage (p56) expressed a higher level of BCRP as compared with the level in the early passages (p33). The total amount of BCRP protein did not change after the cells were confluent. Immunofluorescence studies revealed the positive staining of BCRP on the apical membrane of Caco-2 cells but not on the basolateral membrane after cell confluence. MTX and E3S showed a preferential basolateral-toapical (B-to-A) transport across Caco-2 cell monolayers. Both BCRP inhibitors Ko143 and GF120918 increased the apical-to-basolateral (A-to-B) transport but decreased the B-to-A transport of MTX and E3S. Caco-2 cells may therefore be used as an in vitro model to study the transport characteristics of BCRP.Keywords
This publication has 22 references indexed in Scilit:
- Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain BarrierCancer Research, 2004
- Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)Oncogene, 2003
- Breast Cancer Resistance Protein Exports Sulfated Estrogens but Not Free EstrogensMolecular Pharmacology, 2003
- ABCG2 Transports Sulfated Conjugates of Steroids and XenobioticsJournal of Biological Chemistry, 2003
- Efflux Ratio Cannot Assess P-Glycoprotein-Mediated Attenuation of Absorptive Transport: Asymmetric Effect of P-Glycoprotein on Absorptive and Secretory Transport Across Caco-2 Cell MonolayersPharmaceutical Research, 2003
- Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An OverviewThe Oncologist, 2002
- Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979International Journal of Cancer, 2002
- Role reversal for anticancer agents.Cancer Biology & Therapy, 2002
- From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significanceCellular and Molecular Life Sciences, 2001
- Influence of the Microporous Substratum and Hydrodynamics on Resistances to Drug Transport in Cell Culture Systems: Calculation of Intrinsic Transport ParametersJournal of Pharmaceutical Sciences, 1997